WO2021202201A2 - Methods of disarming viruses using reactive gas - Google Patents
Methods of disarming viruses using reactive gas Download PDFInfo
- Publication number
- WO2021202201A2 WO2021202201A2 PCT/US2021/023941 US2021023941W WO2021202201A2 WO 2021202201 A2 WO2021202201 A2 WO 2021202201A2 US 2021023941 W US2021023941 W US 2021023941W WO 2021202201 A2 WO2021202201 A2 WO 2021202201A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- reactive gas
- gas
- contacting
- hvcp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- A61L2/202—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/14—Plasma, i.e. ionised gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0094—Gaseous substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/26—Accessories or devices or components used for biocidal treatment
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B13/00—Oxygen; Ozone; Oxides or hydroxides in general
- C01B13/10—Preparation of ozone
- C01B13/11—Preparation of ozone by electric discharge
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/11—Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/25—Rooms in buildings, passenger compartments
Definitions
- Biological decontamination and sterilization have a broad array of applications including medical equipment and device sterilization, food production and preservation, and preparation of consumer goods. Chemicals, heat, high-energy electron beams, and X-ray or gamma-ray irradiation systems are presently used for sterilization. Each of these systems has trade-offs due to the cost, efficiency, immobility, electric power requirements, toxic waste, personal hazard and the time required for sterilization or decontamination.
- Plasmas have been used for decontamination and sterilization.
- Plasma a fourth state of matter distinguished from gas, liquid and solid, may be produced through electrical discharge, for example electrical discharge through a gas.
- plasmas contain electrons, ions and neutral species, they will have different properties depending on the composition of the gas used to prepare the plasma, as well as the electrical and structural configuration of the device used to produce the plasma.
- HVCP high-voltage cold plasma
- DBD dielectric barrier discharge
- HVCP may be prepared through a non-equilibrium breakdown of a gas, using voltages preferably of 30 kV to 500 kV, typically at a frequency of 50 or 60 Hz with a DBD system.
- HVCP has not been studies as well as other types of plasmas, such as thermal plasma or RF plasmas. Consequently, there is presently no theory which explains the properties of these plasmas, nor the various excited and reactive species produced in such plasma. Over the last decade experimental examination of HVCP has been carried out to study this plasma.
- Ozone gas has been recognized as a disinfectant, and ozone has been used to treat surfaces in order to remove odors, such as smoke odor. Ozone is capable of killing viruses.
- Ozone treatment is an integral part of many water and wastewater treatment facilities (Wolf, C., et al., “Proxies to monitor the inactivation of viruses by ozone in surface water and wastewater effluent”, Water Research,
- Ozone has also been used to treat products, such as fruit (Brie, A., et al., “Inactivation of murine norovirus and hepatitis A virus on fresh raspberries by gaseous ozone treatment", Food Microbiol., vol. 70, pg. 1-6 (2018)). These treatments make water and products safe for consumption.
- influenza virus may be spread through contact, large respiratory droplets and small particle droplet nuclei (aerosols), and even from contaminated surfaces.
- experimental studies have demonstrated that influenza virus can remain infectious in small particle aerosols, and can transit across rooms (Cowling BJ, et al., “Aerosol transmission is an important mode of influenza A virus spread.” Nat Commun., 4, 1935 (2013)).
- Corona viruses and rotaviruses can spread by contact with a contaminated surface. Measles is similarly contagious.
- Ozone has been used as a virus decontaminating agent (Hudson JB, et al.,
- a prototype device containing 8 corona discharge units, a circulating fan, and a catalytic converter to convert ozone back to oxygen after the treatment.
- the present invention is a method of disinfecting a surface suspected of contamination with a virus, including producing a reactive gas by forming a high-voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20kV to 150kV; transporting the reactive gas at least 1 meter away from the HVCP; followed by contacting the surface with the reactive gas to disinfect the surface.
- HVCP high-voltage cold plasma
- DBD dielectric barrier discharge
- the present invention is a method of disinfecting a surface contaminated with a virus, including producing a reactive gas by forming a high- voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20kV to 150kV; transporting the reactive gas at least 1 meter away from the HVCP; followed by contacting the surface with the reactive gas to disinfect the surface.
- HVCP high- voltage cold plasma
- DBD dielectric barrier discharge
- a cold plasma refers to plasma which has a temperature of at most 40 °C above the temperature of the gas used to prepare the plasma (that is, the working gas), more preferably a temperature of at most 20 °C above the temperature of the gas used to prepare the plasma.
- High-voltage cold plasma means a cold plasma prepared using a dielectric barrier discharge (DBD) system, using voltages of at most 500 kV, with a frequency at most to 5000 Hz, prepared from a gas having a pressure of 10 to 50000 Torr, such as 760 Torr (atmospheric pressure).
- HVCP is not a thermal plasma, is not a microwave plasma and is not a radio frequency (RF) plasma. HVCP plasmas are generated under non-equilibrium breakdown conditions.
- Reactive gas means the gas produced by an HVCP, including excited and chemically reactive species, but not those species which dissipate in 0.2 seconds or less. The composition of a reactive gas will change over time as excited species dissipate and chemical reactions within the reactive gas take place. Reactive gas is the gas that may be moved away from the DBD system that is producing an HVCP.
- a reactive species or excited species is considered to be present in a reactive gas if it can be detected using spectroscopy.
- Dielectric barrier discharge means a system having at least two electrodes separated by a dielectric barrier, and may have more electrodes, where a dielectric barrier is present between each electrode, to prevent charge generated in the gas by a discharge from reaching an electrode.
- the shortest distance between adjacent electrodes in a DBD system is preferably at most 30 cm (or 12 inches), and preferably is at least 0.5 cm (or 0.25 inches).
- DBD systems are configures to operate under conditions to produce an HVCP. Examples of DBD systems are illustrated in FIG. 1A, 1 B, 1C, 1 D, 1E and 1 F; preferably, the electrodes are spaced apart with a gap or plenum directly between the electrodes as illustrated in FIG. 1A, 1B, 1C and 1F.
- Working gas and working gas mixture refers to the gas which is used to form a plasma.
- Package means a container having a volume of at most 6 gallons (or 22.7 liters).
- Sealed or substantially sealed means that the gases inside the package or container remains inside and not flow or diffuse out of the package or container for at least 24 hours, if left undisturbed.
- infectious means that the virus has been destroyed and/or any virus present can no longer cause disease.
- a “host” means a human, animal, or plant in which the virus causes disease or in bacteria, the virus causes lysis of the bacteria.
- a surface contaminated with a virus means that a virus is present on a surface.
- a surface suspected of contamination means that a host who is infected with the virus has contacted the surface.
- contacted a surface includes physical contact, as well as exposing a surface to large respiratory droplets, small particle droplet nuclei (aerosols), or other shedding of virus.
- the protocol may be referred to as a “MS2 phage plaque assay test”. This protocol may be used to validate the effectiveness of a treatment for reducing the amount of virus by providing MS2 phage samples as a proxy for other viruses, and treating the samples to measure the amount of MS2 phage reduction that resulted from the treatment.
- the protocol includes comparing the treated MS2 phage samples to untreated MS2 phage samples for use as a control. First, a solution containing the MS2 phage is spotted onto the surface of several sterile filter papers. The filter papers are allowed to dry and placed in a clean container at 4°C prior to experimental treatment.
- the treated filter papers are treated with reactive gas (or other disinfectant treatment).
- the untreated filter papers are stored and not exposed to any treatment in order to serve as a control.
- the treated filter papers are placed into sterile plastic containers and transported in a chilled cooler to a laboratory for extraction using SM buffer (see Table 7, below, for the specific SM buffer formula).
- SM buffer see Table 7, below, for the specific SM buffer formula.
- the treated and untreated papers are aseptically sliced into 0.5 cm wide strips which are stacked and subsequently cut into 50 ml sterile tubes.
- SM buffer (5 mL) is added to each tube and extraction of the phage is performed over the course of 10 minutes. Just after the buffer is added and at each 2-minute interval during the 10 minutes, each sample is gently pulse-vortexed for 15 seconds.
- the tubes are centrifuged at 5000 rpm at 4°C.
- the supernatant containing residual phage is then filtered through 0.22 uM nylon syringe filters into 15 ml sterile tubes. This supernatant will be added to a host E. coli culture.
- Several dilutions of the treated and untreated filter papers extracts are made and the concentrations of recovered phage are determined by plaque assay using TSB top agar and bottom agar plates. It may be necessary to perform more dilutions to obtain a phage concentration that produces an appropriate number of plaques.
- 0.15 ml of the 3-hour bacterial culture is diluted 1 :5 in TSB and is added to 3 ml of melted top/soft agar maintained at 42-45°C by a water bath, followed by addition of 15 ⁇ l of diluted MS2 phage extract. The mixture is then vortexed gently, poured on bottom agar plates, and allowed to solidify. The plates are then incubated upside down, overnight in a 37°C incubator. The following day, the formed plaques (clear areas) on the plates are counted and results tabulated.
- the E. coli culture is begun by inoculating 10 ml of TSB broth with 100 ⁇ l of E. coli suspension and growing the bacteria culture overnight in a 37°C incubator. The following day, the overnight culture is used to start another fresh E. coli culture. 1 ml of the overnight culture is added to 9 ml of fresh TSB medium (1:10 dilution of overnight culture) and grown for 3 hours in the same conditions. This fresh culture is then diluted 1:5 in TSB medium and used as the bacteria hosts.
- a 2-logio reduction means that the amount of active virus that is present on a surface after treatment is 1/100 th of the amount of active virus that was present prior to the treatment, as determined by the MS2 plaque assay test; this test does not require that the virus of interest is actually present prior to treatment, but rather is a measure of the virus killing ability of the treatment.
- an X-logio reduction where X is 3, 4, 5, or 6, means that the amount of active virus that is present on a surface after treatment is 1/1000th, 1/10, 000th, 1/100,000th and 1/1 , 000, 000th of the amount of virus that was present prior to the treatment, respectively.
- FIG. 1 A, 1 B, 1C, 1 D, 1 E and 1 F are schematic illustrations of a variety of DBD systems.
- FIG. 2 is a schematic illustration of a reactive gas treatment system for continuous treatment of a product or a surface with a reactive gas.
- FIG. 3 is a schematic illustration of a reactive gas treatment system for batch treatment of a product or a surface with a reactive gas.
- FIG. 4 is a schematic illustration of a reactive gas treatment system for treatment of equipment and/or surfaces with an enclosed space.
- FIG. 5 is a graph showing effect of MS2 phage on E. coli growth rate for various data sets, relative to the E. coli control.
- FIG. 6 is a graph showing effect of MS2 phage on E. coli growth rate for various data sets, relative to the E. coli control.
- FIG. 7 is a graph showing effect of MS2 phage on E. coli growth rate for various data sets, relative to the E. coli control.
- FIG. 8 is a graph of host cell count after exposing to filter paper extracts of negative control, positive control and RGS-treated Zika virus.
- FIG. 10 is a graph showing deactivation of bacteriophage SBA 1781 using RGS.
- FIG. 13 is a graph showing the reduction of B. atrophaeus spores over exposure time.
- FIG. 14 is a graph showing the reduction of B. atrophaeus spores over exposure time for a high-flow system (orange) and a standard-flow system (blue).
- FIG. 15 is a graph showing the log reduction of spores over exposure time for a high-flow system (orange) and a standard-flow system (blue).
- FIG. 16 is a graph showing the population of B. atrophaeus spores over exposure time for a high-flow system (orange) and a standard-flow system (blue).
- FIG. 17 is a graph showing reduction of S. enterica cells over exposure time for air reduction (orange) and reactive gas species reduction (blue).
- FIG. 18 is a graph showing reduction of S. enterica cells over exposure time for air reduction (orange) and reactive gas species reduction (blue).
- FIG. 19 is a graph showing the log reduction of E. coli populations for various initial populations.
- FIG. 20 is a graph showing the reduction of E. coli populations for various initial populations as a ratio of initial to final population.
- FIG. 21 is a graph showing the reduction of increasing E. coli population densities.
- FIG. 22 is a graph showing the log reduction of increasing E. coli population densities.
- FIG. 23 is a graph showing the gross reactive gas species reduction and reduction by residual peroxide, for the four populations with peroxide effects within the countable range of experimental conditions.
- the present invention makes use of reactive gas produced by HVCP.
- the reactive gas is able to disinfect surfaces even when transported a significant distance from the DBD system where the plasma is produced, for example 3 to 30 meters (or 10 to 100 feet). Furthermore, the reactive gas is able to disarm viruses. This is quite surprising, because unlike HVCP produced within a package, there is no direct exposure of the product to the HVCP, the contact time of the reactive gas with the product is limited, for example for 1 second, 1 minute, 30 minutes, or one hour. Preferably, the plasma does not contact the surface. Furthermore, because the reactive gas is transported away from the DBD system where the HVCP is produced, it is diluted by both diffusion into the surrounding gas, and mixed with the surrounding gas and/or the working gas.
- the reactive gas Since the reactive gas is transported away from the DBD system, larger surfaces may be treated. In addition, large scale disinfection, such as disinfection of a vehicle or room may also be carried out. Furthermore, the effectiveness of the reactive gas is expected to be greater than what would be expected from the ozone content alone.
- viruses can be ranked with respect to their tolerance to disinfectants (EPA, “Guidance to Registrants: Process for Making Claims against Emerging Viral Pathogens Not on EPA-Registered Disinfectant Labels”, published on August 19, 2016).
- EPA Environmental Protection Agency
- CDC Centers for Disease Control and Prevention
- viruses are divided into three subgroups: small non-enveloped, large non-enveloped and enveloped viruses. According the hierarchy, if a disinfectant can kill a small non-enveloped virus it should be able to kill any large non-enveloped virus and any enveloped virus.
- a disinfectant that can kill a large, non-enveloped virus can kill any enveloped virus.
- the reactive gas of the present application kills MS2 phage virus, as shown by Examples 1 and 4.
- MS2 phage is a small, non-enveloped virus. As killing this virus is the most challenging, the reactive gas would be expected to also kill any virus from the other subgroups. This expectation is borne out by the killing of the zika virus and Salmonella enterica bacteriophage, as shown in Examples 2 and 3 respectively.
- coronaviruses are classified as an enveloped virus, so the reactive gas would be expected to kill coronavirus and disinfect a surface, if coronavirus was present prior to treatment with the reactive gas.
- the reduction may be at least a 2-logio reduction, a 3-logio reduction, a 4- log-io reduction, 5-logio reduction, or a 6-logio reduction in the activity of the virus.
- the MS2 phage plaque assay test may be used to determine the effectiveness of the disinfection. This test does not require that the virus of interest is actually present prior to treatment, but rather is a measure of the virus killing ability of the treatment. Detection of the amount of virus may also be done using classic analytical testing techniques such as ELISA or microscopic determination.
- the duration of the contacting with the reactive gas may be increased in order to further reduce the amount of active virus.
- the contacting of a surface with reactive gas may also be repeated to further reduce the activity of virus.
- the virus may be a DNA virus or an RNA virus.
- the DNA or RNA virus may be further classified as single stranded (ss), double stranded (ds), linear and/or circular.
- the entire virus genome may occupy either one nucleic acid molecule (monopartite genome) or several nucleic acid segments (multipartite genome). The different types of genome necessitate different replication strategies.
- the virus may be identified by the common virus name or the disease caused by the virus.
- the virus may also be identified by the organism from which the virus originated or in which the virus is endemic. It is understood that the common virus names identified herein may refer to various strains of viruses that have similar characteristics or are genetically related to the viruses associated with the common virus name.
- the virus may be a DNA virus, such as a virus from the DNA virus family of Asfarviridae (such as African swine fever virus (ASF)); Adenoviridae (such as Adenovirus and infectious canine hepatitis virus); Papovaviridae (such as Papillomavirus, polyomaviridae, and simian vacuolating virus); Parvoviridae (such as parvovirus B19 and canine parvovirus); Herpesviridae (such as herpes simplex virus, varicella-zoster virus (also known as chicken pox virus), cytomegalovirus, and Epstein-Barr virus); Poxviridae (such as smallpox virus, cow pox virus, sheep pox virus, orf virus, monkey pox virus, and vaccinia virus); Anelloviridae (such as Torque teno virus); or Pleolipoviridae (such as HHPV1 , HRPV1, HGP
- the virus may be an RNA virus, such as a virus from the RNA virus family of Reoviridae (such as reovirus and rotavirus (also called rotovirus)); Picornaviridae (such as enterovirus, rhinovirus, hepatovirus, cardiovirus, aphthovirus, poliovirus, parechovirus, erbovirus, kobuvirus, teschovirus, and coxsackie); Caliciviridae (such as norwalk virus); Togaviridae (such as rubella virus and alphavirus); Arenaviridae (such as lymphocytic choriomeningitis virus); Flaviviridae (such as dengue virus, hepatitis C virus, yellow fever virus, and Zika virus); Orthomyxoviridae (such as influenza virus, isavirus, and thogotovirus); Paramyxoviridae (such as measles virus, mumps virus, respiratory syncytial virus, Rinder
- rotavirus examples include A, B, C, D, E, F, G, H, I or J rotavirus.
- coronavirus examples include Middle East respiratory syndrome coronavirus (MERS), severe acute respiratory syndrome coronavirus (SARS), and COVID-19 virus, as well as coronaviruses that cause the common cold.
- MERS Middle East respiratory syndrome coronavirus
- SARS severe acute respiratory syndrome coronavirus
- COVID-19 virus examples include coronaviruses that cause the common cold.
- the virus that causes COVID-19 is also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- An example of arterivirus is porcine reproductive and respiratory syndrome virus (PRRSV).
- influenza virus examples include influenza virus A, influenza virus B, and influenza virus C.
- Influenza virus variants are sometimes named according to the species (host) in which the strain is endemic or to which it is adapted.
- the influenza virus may be known as bird flu (also known as avian flu), swine flu, human flu, equine flu, and canine flu.
- Influenza virus A species may be further classified by a combination of two groups of proteins: hemagglutinin or “H” proteins and neuraminidase or “N” proteins (" Influenza Type A Viruses". Centers for Disease Control and Prevention https://www.cdc.gov/flu/avianflu/influenza-a-virus- subtypes.htm.
- Examples of different serotypes of Influenza virus A include H1N1 , H1N 2 , H 2 N 2 , H3N1 , H3N 2 , H3N8, H5N1, H5N 2 , H5N3, H5N8, H5N9, H7N1, H7N 2 , H7N3, H7N4, H7N7, H7N9, H9N 2 , H10N7.
- the virus may be a reverse transcribing virus from the virus family of Retroviridae (such as human immunodeficiency virus (HIV)); Caulimoviridae (such as Caulimovirus, and Cacao swollen-shoot virus); or Hepadnaviridae (such as Hepatitis B virus).
- Retroviridae such as human immunodeficiency virus (HIV)
- Caulimoviridae such as Caulimovirus, and Cacao swollen-shoot virus
- Hepadnaviridae such as Hepatitis B virus
- the virus may be present on a product or a surface, or may be present in the air.
- the reactive gas may disarm virus that is present in the air in aerosol droplets or larger droplets.
- the reactive gas may contact the interior surfaces of a man-made structure.
- the man-made structure may be a vehicle, such as a plane, a train, or an automobile.
- the man-made structure may be a room or passage.
- the room may be a room in a hospital or a cruise ship cabin.
- the room may be a room or rooms in a hotel.
- the room may be an office or meeting space.
- the room may be a theater or sports arena.
- FIG. 1A, 1B, 1C, 1D, 1E and 1F are schematic illustrations of a variety of DBD systems which may be used to produce HVCP which produces a reactive gas.
- a DBD system includes a high voltage source, 10, having a ground which generates an alternating current, a first electrode, 20, a second electrode, 30, and an intervening dielectric, 40.
- One or more additional intervening dielectrics, 60 may also be present between the first and second electrode.
- the dielectric may surround the first and/or second electrode.
- the charge accumulation on the electrodes, used in conjunction with the voltage waveform may be used to estimate the power consumption of the DBD system, and may be measured by determining the voltage developed across a conventional capacitor or other sensor, 70.
- a plenum, 50 is present, which defines a space between the electrodes where the HVCP and the reactive gas are produced, as shown in FIG. 1A, 1B, 1C and 1F.
- the HVCP and reactive gas may also be produced in the vicinity of the dielectrics even when a clear plenum is not present in the DBD system, such as illustrated in FIG. 1D and 1E.
- multiple electrodes such as 3 to 21 electrode, 11 to 15, 4 to 8 electrodes, or 5 to 7 electrodes, with one or more intervening dielectrics between each pair of adjacent electrode, and optionally forming multiple plenums, may be used, such as that illustrated in FIG.
- each electrode-dielectric assembly such as 40, 20, and 40
- each plenum 50
- the configuration of the DBD system results in limiting of the current of any filamentary discharge that is formed between the electrodes so as to prevent the formation of a high current arc.
- a first electrode is fully enclosed in a dielectric, and a second electrode is grounded.
- the electrodes may be formed from any conductive material, such as a metal.
- the dielectrics may be formed from any insulating material (dielectric material), such as ceramics, glass, organic materials, or plastics, including multiple layers of various compositions.
- the thickness of the dielectric, or different layers of dielectric should be selected to limit the current of any filamentary discharge that may form between the electrodes. Selection of materials for the dielectric layers may have an effect on the reactive gas composition.
- the distance between adjacent electrodes when the electrodes are parallel, or the shortest distance between adjacent electrodes when the electrode are not parallel, is preferably at most 30 cm (or 12 inches), and preferably is at least 0.5 cm (or 0.25 inches), such as 1 to 10 cm, or 2.5 to 6 cm (or 1 to 2 inches), including 2, 3, 4, 5, 6, 7, 8 and 9 cm.
- the high voltage source produces a voltage of at most 500 kV, more preferably 20 kV to 150 kV, including 30, 40, 50, 60, 70, 80, 90, 95, 100, 110, 120, 130 and 140 kV; having a frequency of at most 5000 Hz, more preferably 10 to 100 Hz, such as 50 to 60 Hz.
- Time variant (that is, pulsed) DC power may also be used.
- the frequency is chosen primarily for convenience (for example, 50 or 60 Hz AC power is available from the municipal power grid), voltage is selected to ensure the production of HVCP.
- the structure of the electrode system and/or dielectric barrier discharge system may be the system described in U.S. Patent Application No. 16/442,380. [67] Different selection of working gases and working gas mixtures will affect the species present in the reactive gas produced by the HVCP.
- gases which may be used to prepare the HVCP include oxygen (O 2 ); nitrogen (N 2 ); water vapor (H 2 O); inert and noble gases such as helium (He), neon (Ne), argon (Ar), krypton (Kr), xenon (Xe) and sulfur hexafluoride (SF 8 ); hydrogen (H 2 ); carbon dioxide (CO 2 ) and carbon monoxide (CO); halogens and pseudo-halogens such as fluorine (F2), chlorine (Cb), bromine (Eta), and cyanogen ((CN) 2 ); acidic gases such as hydrogen sulfide (H 2 S), hydrogen fluoride (HF), hydrogen chloride (HCI), and carbonyl sulfide (COS); ammonia (NH 3 ); hydrazine (H 4 N 2 ); nitrogen trifluoride (NF3); chlorine dioxide (CIO 2 ); hydrocarbons such as methane (CH 4 ), ethane (C2H6)
- Preferred gases include air and MA65 (a mixture of 65% O 2 , 30% CO 2 , and 5% N 2 ). Increasing the amount of water vapor in the gas may be used to reduce ozone present in the reactive gas. Increasing the amount of noble gas, such as helium, may be used to reduce the voltage needed to produce the HVCP.
- the pressure of the gas use to prepare the HVCP is conveniently selected as ambient or atmospheric pressure, but other pressures may be used, such as 10 to 50000 Torn, more preferably 100 to 1000 Torr, such as 760 Torr (atmospheric pressure).
- the reactive gas contains a variety of reactive and excited species, and the reactive gas always contains at least one (and typically more than one) reactive and/or excited species which is not present in the working gas.
- the working gas contains oxygen (for example, O 2 , CO 2 , and/or H 2 O) ozone may form; however, the properties and reactions of the reactive gas are not explained by the presence of ozone alone, and the reactive gas always contains other reactive and excited species in addition to any ozone (which may, or may not be present in the reactive gas).
- reactive and excited species which may be present in reactive gas include: singlet oxygen ( 1 O 2 ) and other excited molecular species (both vibrationally excited molecules and electronically excited atoms and/or molecules, such as O 2 , H 2 , N 2 , CO, CO 2 , H 2 O, He, Ne, Ar, Kr and Xe), hydroxyl radical (HO ⁇ ), nitrogen oxides (such as N 2 O, NO, NO 2 , NO 3 , N 2 O 3 , N 2 O 4 and N 2 O 5 ), hydrogen peroxide (H 2 O 2 ), hydroperoxyl (HO 2 ), HNOx species (such as HNO4, HNO 3 and HNO), atomic radicals (such a O, F, Cl, N and H), and molecular radicals (such as hydrocarbon radicals, which may also contain one or more of oxygen, nitrogen, fluorine and chlorine).
- singlet oxygen 1 O 2
- other excited molecular species both vibrationally excited molecules and electronically excited atoms and/or molecules, such as O 2 , H
- the reactive gas has at least one additional reactive and/or excited species in addition to ozone and NO 2 (or N 2 O4) (which may, or may not, be present).
- reactive gas is not a plasma and does not contain free electrons.
- the reactive gas contains at least 2 different reactive and/or excited species listed above, more preferably at least 3 different reactive and/or excited species listed above, even more preferably at least 4 different reactive and/or excited species listed above, and most preferably at least 5 different reactive and/or excited species listed above, including 2-10 or 3-8 or 4-6 different reactive and/or excited species listed above.
- the stored reactive gas is used to treat a product or surface within 24 hours after it is produced, more preferably within 12 hours, most preferably within 6, even more preferably within 3 hours.
- the reactive gas may also be captured and stored by cooling to extremely low temperatures, for example using liquid nitrogen as a coolant, or using liquid helium as a coolant. When captured and stored at such low temperatures, the reactive gas may be stored for extended periods of time, for example 1 day to 6 weeks, and possibly longer. Containers, such a glass or metal containers used to store other liquefied or solidified gases, may be used.
- a reactive gas treatment system includes either a DBD system or stored reactive gas, and a treatment chamber.
- the reactive gas treatment system also includes a device, mechanism, or a configuration for moving the reactive gas away from the DBD system (which produces a HVCP, which in turn produces the reactive gas) or from a container having stored reactive gas, and into or throughout the treatment chamber; this may be a fluid connection between the DBD system and the treatment chamber.
- the treatment chamber is not sealed; such an unsealed chamber would include a treatment chamber with a gas outlet.
- the treatment chamber has a volume of at least 28 liters (or 1 cubic foot), more preferably a volume of at least 1 cubic meter, and even more preferably at least 8 cubic meters. Examples of treatment chambers include rooms, bins, grain dryers, silos, tanks and shipping containers.
- the reactive gas system may be used to carry out a method of treating a product and/or a surface, by supplying the reactive gas (either from stored reactive gas, or by generating a HVCP using a DBD system), and distributing the reactive gas into or throughout the treatment chamber.
- a device, mechanism, or configuration for moving the reactive gas includes convection, a gas pathway or gas line, a fan, and supplying flowing or pressurized working gas to the DBD system.
- the product or surface treated by the reactive gas is not heated (that is, its temperature is not increased) by the method of treatment by more than 40 °C, more preferably by not more than 20 °C, even more preferably by not more than 10 °C, and most preferably by not more than 5 °C, such as no heating of the product or surface.
- Treatment with the reactive gas is a non-thermal processing method.
- products or surfaces are not exposed to radiation (such as UV light) produced by a HVCP during the method.
- air, a working gas, or another gas such as a noble gas or nitrogen
- the treatment chamber may be evacuated.
- the method may be optionally repeated 1 , 2, 3 or more times, to provide multiple treatments to products or surfaces.
- product may be sealed into a container and/or refrigerated after treatment with a reactive gas.
- the product to be treated is not enclosed in a sealed or substantially sealed contain, such as a container have a volume of at most 10 gallons, or at most 6 gallons, during treatment.
- the HVCP is not produced inside a sealed container, such as a container have a volume of at most 10 gallons, or at most 6 gallons.
- the reactive gas produced by the HVCP is transported away from the site of production of the HVCP (to avoid direct exposure of the product or surface to the HVCP), by diffusion or gas transfer.
- the distance between the plasma and the product or surface to be treated is at least a distance of 5 cm, such as at least 10 cm, at least 50 cm, and at least 1 meter (or 3.28 feet), more preferably at least 3 meters, for example 3 to 300 meters, including 5, 10, 20, 30, 40 and 50 meters.
- the reactive gas is allowed to flow while it is in contact with a product or surface to be treated, although it is also possible to produce the reactive gas and transfer it to a site to treat the product or surface, and confine the gas to the treatment location for a period of time.
- Examples of flow rates for transferring the reactive gas to a location for contact with a product or surface include 10 to 3000 meters/minute, 30 to 2500 meters per minute, and 1000 to 2000 meters/minute, such as 50, 100, 200, 300, 400, 500, 750, and 1500 meters/minute.
- the reactive gas is allowed to contact the product or surface for at least 1 second, for example at least 2 seconds, at least 10 seconds, at least 30 seconds, at least 1 minute, at least 10 minutes, at least 30 minutes, at least 35 minutes, at least 1 hour, at least 6 hours, or at least 12 hours.
- Examples of contact times include 1 second to 12 hours, 10 seconds to 1 hour, 1 minute to 35 minutes, including 5 seconds, 15 seconds, 2 minutes, 5 minutes, 20 minutes, 35 minutes, 40 minutes, 2 hours, 3 hours, 4 hours and 5 hours.
- FIG. 2 is a schematic illustration of a reactive gas treatment system, 200, for continuous treatment of a product or a surface with a reactive gas.
- the system includes a DBD system, 206, for generating a HVCP to produce a reactive gas, 210.
- the reactive gas flows along a gas pathway, 208, into a treatment chamber, 216, and then out a gas outlet, 222.
- Product, 214, to be treated or which has a surface to be treated may be stored in a hopper, 212, as it is fed into the treatment chamber, and onto a conveyor, 218, which moves the product through the treatment chamber and into a receiving bin, 220, for hold the product after it has been contacted with the reactive gas.
- a gas source such as a gas tank, which provides a working gas from which the HVCP is formed
- a gas line, 204 which supplied the DBD system with the working gas.
- the reactive gas may be diluted with additional working gas as it flows through the system.
- the transport of the reactive gas from the DBD system to the treatment chamber is by way of a pressure differential between the DBD system (at higher pressure from introduction of the working gas) and the treatment chamber (at lower pressure due to the gas outlet).
- the gas outlet may be connected back to the DBD system by a second gas line, allowing for recycling of the working gas and any remaining reactive gas.
- the DBD system may be located inside the treatment chamber, avoiding the need for a gas pathway.
- the working gas may be air
- the transport of the reactive gas may be caused by a fan located in the gas pathway (blowing the reactive gas into the treatment chamber) or at the back of the DBD system (blowing air through the DBD system).
- the conveyor may transport the product on a screen to ensure that the reactive gas comes into contact on all surfaces of the product.
- product may be moved through the treatment chamber on a plurality of conveyors, where the product is shifted around as it moves from a first conveyor to a second conveyor, ensuring that the reactive gas comes into contact with all surfaces of the product.
- the DBD system may be eliminated, by using a stored reactive gas as the gas source and transporting the reactive gas directly to the treatment chamber.
- a variety of different conveyors may be used, such as a permeable belt conveyor, a screw, a tunnel dryer, a grain dryer, a fluid bed dryer or a cylindrical dryer.
- FIG. 3 is a schematic illustration of a reactive gas treatment system, 300, for batch treatment of a product or a surface with a reactive gas.
- the system includes a DBD system, 306, for generating a HVCP to produce a reactive gas.
- the reactive gas flows along gas pathways, 308 and 312, into a treatment chamber, 302, and then out through a gas pathway, 316, through an optional product recovery trap, 318, along a gas pathway, 320, and out through a gas outlet, 324.
- Some or all of the reactive gas and working gas may be recycled back to the DBD system through an optional gas pathway, 304.
- the reactive gas and working gas is propelled through the system by fans, 310 and 322.
- Product, 314, to be treated or which has a surface to be treated is present in the treatment chamber; as illustrated the reactive gas is fed in through the bottom of the treatment chamber to create a fluidized bed from of the reactive gas and the product to ensure treatment of all surfaces of the product.
- the product recovery trap may be used to capture any product which exits the treatment chamber and into the gas pathway and return it back to the treatment chamber.
- the treatment chamber may be a silo in the system illustrated; other treatment chambers include a fluid bed, a mechanical fluid bed, and a bin.
- the reactive gas may be diluted with addition working gas as it flows through the system. As illustrated, the working gas may be air, but optionally the gas pathway, 304, may be connected to a gas source for supplying a working gas to the DBD system. In another variation, the DBD system may be eliminated and replaced with stored reactive gas.
- Examples of products includes fresh foods (such as fruits, vegetables, grains, beans, seeds, meat, dairy products, eggs, and spices or seasonings), seafood (fish and shell fish, and their parts), prepared foods, frozen foods, processed foods prior to packaging (water, beverages, baby food, liquid eggs, fruit juice, flour, oil, nutritional product, vitamins, nutraceuticals and baked foods), packaged products (for treatment of the exterior of the packages), animal feed, cans, bottles, plastic containers, food containers, cookware and utensils; pills, capsules, unit dosage forms and powders; medical devices and medical equipment, both before use and after use; laboratory glass and plastic ware; ceramic products; metal products; and leather and wood products.
- fresh foods such as fruits, vegetables, grains, beans, seeds, meat, dairy products, eggs, and spices or seasonings
- seafood fish and shell fish, and their parts
- prepared foods frozen foods
- processed foods prior to packaging water, beverages, baby food, liquid eggs, fruit juice, flour, oil, nutritional product, vitamins, nutraceuticals and baked foods
- packaged products for treatment of
- disinfection is not accomplished by treatment with the reactive gas, successive treatments may be conducted. For example, 1 to 10 treatments may be carried out, or 2 to 9 treatments, including 3, 4, 5, 6, 7 or 8 treatments may be carried out. Similarly, the time of treatment may also be extended.
- FIG. 4 is a schematic illustration of a reactive gas treatment system for treatment of equipment and/or surfaces with an enclosed space, such as a room, a shipping container, a trailer or a refrigerated truck.
- a DBD system 406 for generating a HVCP to produce a reactive gas, 408.
- a fan, 410 is used to distribute the reactive gas throughout the enclosed space.
- product or surfaces to be treated which includes the walls or interior surfaces of the enclosed space, optional equipment, 414, such a medical equipment (for example, surgical instruments, masks, assisted breathing equipment, and vital sign monitors), and/or optional surfaces, 412, such as a surgical table, to be treated with the reactive gas.
- supports, 402 could be used to mount the DBD system to the top or the sides of the enclosed space, or the DBD system could be place on the floor of the enclosed space.
- a working gas supply could be supplied by a gas line, 404, connected to a gas supply (not illustrated).
- the enclosed space could be filled with a working gas.
- the DBD system could be replaced with stored reactive gas.
- Example 1 The Effect of Reactive Gas on Viral Activities and Inactivation:
- This example describes the use of a reactive gas transported 21 feet (640 cm) on a MS2 bacteriophage for effectiveness on killing viruses.
- the MS2 bacteriophage is an RNA virus that infects Escherichia coli ( E . coli ) and other bacterial members of Enterobacteriaceae. Since most human viral pathogens are RNA viruses, MS2 bacteriophage (a non-human pathogen) was chosen as a model system for viral inactivation.
- MS2 bacteriophages are a commonly used model for human viruses (Kuzmanovic, D.A., et al., “Bacteriophage MS2: Molecular Weight and Spatial Distribution of the Protein and RNA Components by Small-Angle Neutron Scattering and Virus Counting”, Structure, Vol. 11 , 1339-1348 (2003)).
- the MS2 bacteriophage host bacterium used in this study was Escherichia coli (E.coli, strain K-12, ATCC 15597).
- the E. coli (ATCC 15597) in its original vial was purchased from American Type Culture Collection (ATCC) (Manassas, VA) and reconstituted by adding 1 ml of fresh broth medium (1% Tryptone, 0.1% Yeast Extract, and 0.8% NaCI in deionized water). The reconstituted culture (100 ⁇ l), was withdrawn from the vial and used to inoculate 30 ml of same broth medium in culture flasks and grown in a thermal incubator overnight at 37°C. The resulting E. coli culture was then used for propagation of MS2 bacteriophage and screening assay.
- the Bacteriophage, MS2 (ATCC 15597-B1) was propagated in its bacterial host cells, E. coli (strain K-12, ATCC 15597) according to ATCC procedure without using soft/top-agar overlay.
- the host bacterial culture cells were grown overnight in broth at 37°C, as described above. Subsequently, 1.0 ml of host bacterial cells suspension was added to the surface of agar plates and gently tilted to ensure the entire surface coverage with host bacterial cells. The excess liquid was then aspirated from the agar plate and plates were allowed to dry. Solutions of various dilutions of MS2 phage suspension in broth was spotted on the surface of agar plate and incubated overnight at 37°C.
- SM buffer 5 ml was added to each agar plate and stored at 4°C for 3 hours with periodic gentle shaking.
- the SM buffer suspensions were collected and transferred into 50 ml polypropylene tubes and fresh SM buffer (5 ml per plate) was added into each plate followed by further incubation at 4°C for 15 minutes with periodic suspension.
- the buffer was collected and pooled together with previous buffer in the 50 ml tubes and plates discarded.
- the pooled SM buffer-MS2 phage suspension was centrifuged at 5000 x g for 15 minutes at 4°C, to sediment the cellular debris and agar pieces, and the supernatants were collected.
- the resulting supernatants were passed through a 0.22 mM Millipore filter to remove the host bacteria cells, and the filtrate containing the recovered MS2 phage was stored at 4°C for experimental use.
- the filter papers were then dried through evaporation and then exposed to reactive gas transported 21 feet (640 cm) for 30-90 minutes produced using a DBD system at a voltage of 76 kV.
- the electrode gap of the device producing the plasma was 1 .5 inches.
- the papers were sliced into 15 ml sterile tubes and MS2 virus recovered from sliced filter paper pieces through extraction with 5 ml per tube of SM buffer.
- the viral activity in the paper extracts was determined by high-throughput screening using clear 96-well flat bottom plates (purchased from Midwest Scientific (MidSci), St. Louis, MO) and the host bacterial culture (E. coli ). Briefly, E.
- E. coli host cell count from MS2-negative, MS2-positive, and MS2-RGS treatments. Experiment 1 Results.
- (I) Agar Plate [100] 950 ml of deionized water was added for 1 liter or 475 ml for 500 ml media volumes. Medium was autoclaved at 121°C and aseptically, solution B added to the media after autoclaving and cooling down (that is, 50 ml for 1 liter volume or 25 ml for 500 ml volume). The medium was poured into 100 mm Petri Plates prior solidifying (10 ml per plate). The Agar Plates were store at 4°C and used as needed.
- the soft/top agar was prepared in same way as plate agar medium. Half of the Agar amount was weighed into top agar medium (usually agar plates medium contains 15 g agar (1.5% w/v) and top agar 5 - 7.5 g agar (0.5 - 0.75% w/v). After autoclaving, cooling and adding solution B, the soft medium was aliquoted into sterile glass tubes (4 ml per tube) and store at room temperature for future use as needed.
- Example 2 Evaluation of the Effectiveness of Reactive Gas (RGS) as an Antiviral Agent Using Zika Virus (ZIKV).
- This example describes the use of a reactive gas transported 21 feet (640 cm) on a Zika virus for effectiveness on killing viruses.
- This virus is one of the emerging global pathogens responsible for causing birth defects like microcephaly.
- Zika virus has no approved therapies or vaccines and any antiviral agent with inhibitory effects towards its activities will be a useful tool to prevent its infection.
- RGS is suitable as an antiviral agent for the deactivation Zika virus.
- Vero cells ATCC CCL -81 , used for Zika virus propagation and infection were purchased from American Type Culture Collection (ATCC, Manassas, VA).
- Zika virus (ATCC VR-1843 PQ, strain PRVABC59) was also bought from ATCC.
- the cells were grown in high glucose Dulbecco’s modified Eagles medium (DMEM, obtained from ATCC) and supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4 mM L-glutamine, 100 ⁇ g/ml streptomycin, 100 units/ml penicillin, 1 mM sodium pyruvate and non-essential amino acids.
- FBS heat-inactivated fetal bovine serum
- L-glutamine 100 ⁇ g/ml streptomycin
- penicillin 100 ⁇ g/ml penicillin
- 1 mM sodium pyruvate 1 mM sodium pyruvate
- non-essential amino acids 1 mM sodium pyruvate
- Cells were cultured and maintained at 37°C in 5% CO 2 humidified incubator. All tissue culture grade reagents and chemicals were either obtained from ATCC or Millipore-Sigma (St. Louis, MO) and Thermo Fisher Scientific (Waltham, MA).
- the Zika virus (strain PR VABC59) used in this study was propagated by inoculating 70% confluent Vero cells in T75 tissue culture flasks for 2 hours in 3 ml DMEM medium without FBS, at a multiplicity of infection of 0.01 and 0.025, respectively. Then 20 ml of fresh DMEM medium with 10% FBS was added and cells incubated at 37°C in a 5% CO 2 humidified chamber. The cytopathic effect (CPE), used as a measure of host cells killed by Zika virus was monitored by observation under light microscopy. The virus was harvested when Vero cells showed 70% or more cells death or detachment due to CPE. The spent medium was removed and centrifuged for 5 minutes at 3000 rpm. The resulting supernatant was passed through 0.22 mM Millipore filter to remove host cells residue and any contaminating bacteria. The Zika virus containing filtrate was aliquoted and stored at -20°C for future experiments.
- the tubes were then centrifuged at 5000 rpm for 5 min to pellet the filter paper debris, and the resulting supernatant filtered through 0.22-micron filter.
- the filtrates were stored at 4°C for Zika virus activity analysis using 3-[4.5-dimethyl -2- thiaozolyl]-2-5-diphenyl-2H-tetrazolium bromide (MTT) cytotoxicity bioassay.
- the MTT assay is a colorimetric assay for assessing cell metabolic activity.
- NAD(P)H-dependent cellular oxidoreductase enzymes may, under defined conditions, reflect the number of viable cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide to its insoluble formazan, which has a purple color.
- Untreated and RGS-treated Zika virus filtrates were plated in 96-well tissue culture plate containing Vera cells at a seeding density of 6x10 3 cells per well, in final volume of 200 mI of DMEM.
- RGS treatment significantly deactivates Zika virus.
- a 90 minutes RGS treatment reduces Zika virus by approximately 80%.
- RGS treatment could effectively deactivate pathogenic viruses on surfaces, spaces, food, feed, medical equipment etc.
- RGS technology is an effective antiviral treatment against environmental, medical and food-borne viruses.
- Example 3 Salmonella enterica (Newport) Bacteriophage Deactivation Using Reactive Gas (RGS): Use of SBA 1781 Bacteriophage Model to determine the Effectiveness of RGS as an antiviral agent
- Salmonella enterica Bacteriophage SBA 1781 phage virus was used to evaluate the effectiveness of RGS in deactivating viruses.
- Host Bacteria Salmonella enterica (Newport strain, ATCC 6962), purchased from American Type Culture Collection (ATCC), Manassas, VA. Bacteriophage,
- SBA 1781 ATCC designation PTA-5282 was also purchased from ATCC.
- the Salmonella enterica (ATCC 6962) is the natural bacterium host for bacteriophage, SBA 1781.
- the Salmonella enterica bacteria (in a vial) that was purchased from ATCC was reconstituted by adding 1 ml of fresh broth medium (1% Tryptone, 0.1% Yeast Extract, and 0.8% NaCI in distilled H 2 O). The reconstituted bacteria culture (100 ⁇ l), was withdrawn from the vial and used to inoculate 10 ml of same broth medium in a culture glass tube with loose cap. The inoculated broth was grown overnight (18-20 hours) at 37°C in a temperature-controlled incubator. The resulting salmonella enterica overnight culture, was then used for propagation of bacteriophage, SBA 1781.
- the bacteriophage, SBA 1781 was propagated in its natural host cells, the Salmonella enterica culture, using the ATCC recommended procedure. Briefly, the host bacterial culture cells were grown overnight at 37°C, in broth as described above. Thereafter, 1.0 ml of bacterial culture cells suspension was added to the surface of agar plates and gently tilted to ensure the entire surface coverage with host bacterial cells. The excess liquid was then aspirated from the agar plates and the plates allowed to moist dry. Suspensions of various dilutions of Salmonella phage (SBA 1781) in broth were spotted on the surface of agar plates and incubated overnight at 37°C.
- the bacteriophage was harvested by adding 5 ml of fresh broth media per plate and incubated at 4°C for 1 hour with periodic gentle shaking.
- the extract (suspension) from each plate was collected and transferred to a 50 ml sterile polypropylene tube, and another 5 ml fresh media added to each plate for a second extraction (20 minutes) at 4°C, with periodic gentle shaking.
- the two extracts from each plate were pooled in 50 ml conical tubes and the plates discarded.
- the pooled suspension was centrifuged at 5000 x g for 15 min at 4°C, to pellet the cellular and agar debris.
- the supernatants were then collected and passed through 0.22 ⁇ M Millipore filter to remove host bacteria cells.
- the resulting filtrates containing the recovered bacteriophage were stored at 4°C for future experimental use.
- the remaining filter papers were made into three sets and each set treated with RGS using RGS for 30, 60 and 90 minutes, respectively at 80 kV.
- each set of filter papers were sliced into small pieces separately and placed in sterile 50 ml tubes.
- the bacteriophage from the filter papers were extracted with 5 ml per tube of sterile PBS (1X).
- the viral activity in the recovered filter paper extracts was determined by high-throughput screening, using clear 96-well flat bottom plates (purchased from Midwest Scientific (MidSci), St.
- the fresh grown Salmonella enterica culture was diluted to a cell density of 1000 cells/ml suspension in nutrient broth; and plated into 96-well plate (170 mI/well). This was immediately followed by addition of 30 ⁇ l of various dilutions of bacteriophage extract (suspension) to a final volume of 200 mI per well.
- the inoculated 96-well plate was incubated at 37°C for overnight culture growth (18- 20 hours). The overnight culture optical density (OD) was then read at 660 nm using Spectra-Vmax PC340 plate reader (Molecular Devise).
- the absorbance reading obtained were used for computing bacterial growth, as a measure of growth reversal due to deactivation of SBA 1781 virus phage by RGS.
- Both untreated (positive control) and RGS-treated phage were compared with negative control wells (wells without phage) and percentage growth of Salmonella enterica (viabilities) calculated for all treatment groups.
- the effectiveness RGS in inactivating SBA 1781 was determined by comparing the bacterial ( Salmonella enterica) growth difference (% viability) observed in extracts of RGS-treated and untreated (positive control) bacteriophage.
- Example 4 The Disinfection of MS2 Bacteriophage Virus using RGS: Scaled- up Pilot Generator System
- MS2 bacteriophage a single stranded RNA virus spotted on and recovered from surfaces of 90 mm Whatman 5 filter papers.
- MS2 bacteriophage is an RNA virus that infects and lyses Escherichia coli ( E . coli) and other bacterial members of Enterobacteriaceae. Since most human viral pathogens are RNA viruses, MS2 bacteriophage (non-human pathogen) was chosen as an optimal model for determining the effectiveness of RGS treatment on viral disinfection and inactivation.
- the pilot system is an industrially hardened 8kW generation system scaled from a 1kW prototype technology system.
- the improved pilot system version has a significantly greater treatment chamber capacity with capabilities of generating greater amounts of reactive gas species (RGS) via dielectric barrier discharge (DBD) between ten 1 ,5-inch electrode gaps.
- RGS reactive gas species
- DBD dielectric barrier discharge
- the system was operated at 590 cubic feet per minute (cfm) and a voltage of 84kV, which resulted in formation of 30 ⁇ 2 ppm of ozone as measured in the center of the container where samples were treated.
- Gas was passed through the plasma generator and then transported approximately 250 ft through a pneumatic conveying system and then through 4”
- the host Bacteria Escherichia coli ( E.coli , strain K-12, ATCC 15597) was purchased from American Type Culture Collection (ATCC), Manassas, VA. The MS2 Phage: ATCC 15597-B1, was also purchased from ATCC.
- General laboratory consumables, reagents and supplies include: TSB medium broth, agar plates, top agar, pipettors, serological tubes and pipettes, SM phage buffer, syringes, 0.22 mM nylon syringe filters, black plastic SNAP PAK® containers, tweezers, hemostats, scissors, etc.
- the medium includes: TSB Broth, bottom agar plates (100 mm plates) and top agar (3 ml/tube).
- the bottom agar includes: 1.5% agar in TSB broth (15 g per liter or 7.5 g per 500 ml).
- the top agar includes: 0.7% agar in TSB broth (7.5 g per liter or 3.75 g per 500 ml)
- the MS2 bacteriophage host bacterium used in this study was Escherichia coli ( E.coli , strain K-12, ATCC 15597).
- the E. coli (ATCC 15597) in its original vial was purchased from ATCC and reconstituted by adding 1ml of fresh broth medium (1% tryptone, 0.1% yeast extract, and 0.8% NaCI in de-ionized (Dl) water).
- the reconstituted culture (100 ⁇ l), was withdrawn from the vial and used to inoculate 10 ml of the same broth medium in glass culture tubes which were grown in a thermal incubator overnight at 37°C.
- the resulting E. coli culture was then used for propagation of MS2 bacteriophage for treatment and subsequent titrated plaque assays for viruses recovered from untreated/treated samples.
- the Bacteriophage, MS2 (ATCC 15597-B1) was propagated in its bacterial host cells, E. coli (strain K-12, ATCC 15597), according to ATCC procedure without using a soft/top-agar overlay.
- the host bacterial culture cells were grown overnight in broth at 37°C, as described above. Subsequently, 1.0 ml of host bacterial cells suspension was added to the surface of each agar plate and gently tilted to ensure the entire surface coverage with host bacterial cells. The excess liquid was then aspirated from the agar plate and plates were allowed to dry. Solutions of various dilutions of MS2 phage suspension in broth were spotted on the surface of agar plates and incubated overnight at 37°C.
- SM bacteriophage stabilization buffer
- the pooled SM buffer-MS2 phage suspension was centrifuged at 5000 x g for 15 minutes at 4°C to sediment the cellular debris and agar pieces prior to collection of particulate-free virus-laden supernatant.
- the resulting supernatants were passed through a 0.22 ⁇ M nylon syringe filter to remove host bacteria cells, and the filtrate containing the recovered MS2 phage was stored at 4°C for experimental use.
- the filter papers were aseptically removed from their storage container and were clamped with binder clips which had been threaded with cotton twine and hung from magnetic hooks in various locations in the 8’x8’x20’ (length x width x depth) steel container.
- the container had a double door. The right door was completely open and out of the way, and a 1 /2-inch-thick plywood bulkhead panel attached to a 2x4 frame was inserted into the container replacing the open door. A nominal 4” hole was cut into the upper right-hand corner of the plywood panel and a 4” metal duct was inserted through the hole into the container, the duct terminating at the midpoint of the container where it was supported. The 10-foot-long ridged duct was connected to the 4” PVC flexible tubing. The left door was cracked open (1.5 inches) to give the gas an outlet to escape.
- the E. coli culture was started by inoculating 10 ml of TSB broth with 100 ⁇ l of E. coli suspension in the same medium as described above and grown overnight in a 37°C incubator. The following day, the overnight culture was used to start another fresh E. coli culture. 1 ml of the overnight culture was added to 9 ml of fresh TSB medium (1:10 dilution of overnight culture) and grown for 3 hours in the same conditions. This fresh culture was then diluted 1:5 in TSB medium and used as the bacteria hosts in the MS2 plaque assay. Several dilutions of the untreated and treated filter papers extracts were made and the concentrations of recovered MS2 virus were determined by plaque assay using TSB top agar and bottom agar plates.
- the MS2 concentration per ml value in the fifth column of the above table is obtained by dividing the plaque count by 0.015 ml (the volume of MS2 extract which was added to the 15 ml vial containing 0.15 ml of 1 : 5 dilution of 3 hours E. coli, and 3 ml top agar) then accounting for the MS2 dilution factor.
- the filter paper #1 placed in front of the gas entry point to the sample container
- filter paper #3 placed in the back-left corner of sample container
- Example 13A one untreated paper was compared to one treated paper (sample 9) which was hung in the treatment container just in front of the gas inlet.
- Experiment 1 indicated a viable virus reduction of 98.8%, from 6.00 x 10 11 PFUs/mL to 7.47 x 10 9 PFUs/ml.
- one untreated paper (sample 9) was compared to two treated papers. The first treated paper (sample 1) was hung in the treatment container just in front of the gas inlet, while the second treated paper (sample 3) was hung in the back-left corner approximately 14 feet away from the gas inlet.
- sample 3 carries significance because it likely saw significantly less turbulent air flow than sample 1 yet only had a slightly worse virus reduction percentage.
- Experiment 2 indicated viable virus reductions of 99.9% and 99.8%, from 2.67 x 10 10 PFUs/mL to 2.53 x 10 7 and 6.40 x 10 7 PFUs/mL for sample 1 and sample 3, respectively.
- Plating host E. coli cells with extracted MS2-bacteriophage viruses in this bacterial cell-based plaque assay provides a relatively easy method for quantifying virus recovery and reduction.
- Active MS2 phage infects its host cells and lyses (kills) them leading to formation of plaques, characterized by clear areas on the plates. Since each clear area (plaque) represents a single viral particle, plaque quantification allows for determination of virus titer in both control and experimental samples.
- Example 5 The Effect of Reactive Gas Produced at 60 kV on Bacillus atrophaeus Spores at 60, 120 and 180 Minutes at Standard-Flow
- B. atrophaeus spores are considered one of the most difficult microorganisms to kill.
- the following experiment demonstrates the ability of reative gas to kill any microorganisms, including viruses. Additional experiments show the killing of bacteria, which also shows the ability of reactive gas to kill viruses, since the composition of viruses and bacteria is similar.
- Example 6 The Effect of Reactive Gas Produced at 60 kV on Bacillus atrophaeus Spores at 15, 30, 45 and 60 Minutes at Standard-Flow and High-Flow
- Standard-flow was calculated to be a velocity of 80.2 feet/minute, while high- flow was calculated to be a velocity of 2281 feet/minute.
- the temperature was 25 to 40°C with a dew point of 5.3 to 6.7°C, giving a relative humidity of 39.3 to 40.8.
- the “E+” is scientific E notation, where the expression "mE+n" indicates a value of m x 10 n .
- Example 7 The Effect of Reactive Gas Produced at 80 kV on Salmonella enterica on Filter Paper
- Example 8 The Effect of Reactive Gas Produced at 80 kV on Escherichia coli on Filter Paper
- Example 8 was carried out under similar conditions as Example 7. Ten 10 mm Whatman filter papers were inoculated with 8.08E+6 E. coli cells and exposed to reactive gas species (RGS) over a 3-point time-course. Each sample included a batch of 10 filter papers treated simultaneously for 0, 1 , 5 or 15 minutes with RGS generated at 80 kV. Three sets of filters were treated with only air for the respective time points for comparison. All control and experimental samples were inoculated immediately before placement into the treatment chamber, and placed immediately into extraction buffer after treatment. Reduction values for both RGS and air treatments expressed as the log of the change in population over time [Logio(No/N)], are shown in FIG. 18 and Table 12 below.
- Example 9 The Effect of Reactive Gas Produced at 80 kV on Escherichia coli on Tryptone Soya Agar (TSA) [230] An E. coli inoculum was prepared to an O.D. at 625 nm of 0.550. This density is estimated to be 1.8E+9 cells and experimentally confirmed to be 6.95E+9 cells. A series of 7, 1:10 serial dilutions were created from the inoculum resulting in a series of cell suspensions from E+9 cells down to E+2 cells. Three sets of initial population levels of E+8, E+7 and E+6 cells were inoculated onto TSA and treated for 15, 30 and 45 minutes with reactive gas (RGS).
- RGS reactive gas
- Example 10 The Effect of Reactive Gas Produced at 80 kV on Escherichia coli on Tryptone Soya Agar (TSA)
- E. coli cells cultured for 24 hours were concentrated to a starting density of 1.5E+10 and diluted in a series of 7, 1 :10 dilutions.
- One set of 8 TSA plates was inoculated with 0.1 mL of each of the population dilutions resulting in a series of plates with cell populations beginning at 1.51 E+9 through 1 .51 E+2 prior to a 25 minute reactive gas (RGS) exposure.
- RGS reactive gas
- a second set of plates was exposed to a 25 minute RGS exposure and inoculated with cells after the treatment in the same manner as the first series of plates. Reduction values of the pre-inoculated set indicate gross reduction due to all concomitant experimental factors.
- Reduction values of the post-inoculated plates indicate net reduction due to formation of peroxide radicals and acidification within the agar growth medium (note: most agar is 395% water).
- the results are displayed both as initial (No) versus final (N) population curves (FIG. 21) as well as by the magnitude of log reduction (FIG. 22).
- FIG. 23 compares the gross reduction, and reduction by residual peroxide, for the four populations with peroxide effects within the countable range of experimental conditions. (Please note: The ⁇ +” is scientific E notation, where the expression "mE+n" indicates a value of m x 10 n .)
- a first virus sample is taken from a surface prior to treatment with a reactive gas. This virus sample is stored in a cool, sterile container until it is ready to be tested. The surface is then contacted with a reactive gas.
- the reactive gas is produced by forming a high-voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20kV to 150kV and the reactive gas is transported at least 1 meter away from the HVCP.
- HVCP high-voltage cold plasma
- DBD dielectric barrier discharge
- a plaque assay test is performed on the first virus sample and the second virus sample. The number of plaques for each sample will be counted. The plaque forming units per volume (PFUs/mL) for each virus sample will be compared. By comparing the PFUs/mL of the treated and untreated paper, the logio reduction in virus is determined. If the virus concentration of the treated paper is 1.0 x 10 7 PFUs/mL and the virus concentration of the untreated paper is 1.0 x 10 9 PFUs/mL, then the treatment has achieved a 2-logio reduction. If the number of PFUs/mL in the second sample is too high, a second administration of reactive gas may be administered.
- pieces of filter paper may be used to provide uniform virus samples. Two pieces of filter paper may be blotted with a solution containing a virus, preferably MS2 phage.
- One piece of the filter paper (RGS treated) may be placed in a chamber, which has surfaces to be treated. The surfaces in the chamber, including the filter paper, are contacted with a reactive gas.
- the reactive gas is produced by forming a high-voltage cold plasma (HVCP) from a working gas with a dielectric barrier discharge (DBD) system at a voltage of 20kV to 150kV and the reactive gas is transported at least 1 meter away from the HVCP.
- the other piece of filter paper (untreated) is stored in a cool, sterile container until it is ready to be tested. After the reactive gas treatment has been carried out, a plaque assay test is performed on the RGS treated and untreated filter papers.
- NTPs Non-thermal plasmas
- Ozone as a Disinfectant to Destroy Pathogens, like the Coronavirus (www.ozonesolutions.com/knowledge-center/use-ozone-as-a-disinfectant-to-destroy- pathogens-like-thecoronavirus.html) downloaded 3-13-2020.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227038433A KR20220164023A (en) | 2020-04-03 | 2021-03-24 | How to neutralize viruses using reactive gases |
MX2022012346A MX2022012346A (en) | 2020-04-03 | 2021-03-24 | Methods of disarming viruses using reactive gas. |
CN202180039377.6A CN116033928A (en) | 2020-04-03 | 2021-03-24 | Method for virus elimination using reactive gas |
AU2021247032A AU2021247032A1 (en) | 2020-04-03 | 2021-03-24 | Methods of disarming viruses using reactive gas |
JP2022559960A JP2023520787A (en) | 2020-04-03 | 2021-03-24 | Method of Neutralizing Viruses Using Reactive Gases |
EP21721663.9A EP4126081A2 (en) | 2020-04-03 | 2021-03-24 | Methods of disarming viruses using reactive gas |
CA3171198A CA3171198A1 (en) | 2020-04-03 | 2021-03-24 | Methods of disarming viruses using reactive gas |
BR112022019825A BR112022019825A2 (en) | 2020-04-03 | 2021-03-24 | METHODS TO DISARM VIRUSES USING REACTIVE GAS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063005094P | 2020-04-03 | 2020-04-03 | |
US63/005,094 | 2020-04-03 | ||
US17/017,517 US11896731B2 (en) | 2020-04-03 | 2020-09-10 | Methods of disarming viruses using reactive gas |
US17/017,517 | 2020-09-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021202201A2 true WO2021202201A2 (en) | 2021-10-07 |
WO2021202201A3 WO2021202201A3 (en) | 2021-12-02 |
Family
ID=77920963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/023941 WO2021202201A2 (en) | 2020-04-03 | 2021-03-24 | Methods of disarming viruses using reactive gas |
Country Status (10)
Country | Link |
---|---|
US (1) | US11896731B2 (en) |
EP (1) | EP4126081A2 (en) |
JP (1) | JP2023520787A (en) |
KR (1) | KR20220164023A (en) |
CN (1) | CN116033928A (en) |
AU (1) | AU2021247032A1 (en) |
BR (1) | BR112022019825A2 (en) |
CA (1) | CA3171198A1 (en) |
MX (1) | MX2022012346A (en) |
WO (1) | WO2021202201A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11882844B2 (en) | 2015-10-23 | 2024-01-30 | NanoGuard Technologies, LLC | Reactive gas, reactive gas generation system and product treatment using reactive gas |
US11896731B2 (en) | 2020-04-03 | 2024-02-13 | NanoGuard Technologies, LLC | Methods of disarming viruses using reactive gas |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130189156A1 (en) | 2009-03-24 | 2013-07-25 | Purdue Research Foundation | Method and system for treating packaged products |
US20140044595A1 (en) | 2009-03-24 | 2014-02-13 | Purdue Research Foundation | Generation of microbiocide inside a package utilizing a controlled gas composition |
Family Cites Families (168)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2837666A (en) | 1953-07-24 | 1958-06-03 | Ernest G Linder | Radioactive voltage source employing a gaseous dielectric medium |
US3891561A (en) | 1967-01-04 | 1975-06-24 | Purification Sciences Inc | Corona generator apparatus |
JPS58220659A (en) | 1982-06-16 | 1983-12-22 | House Food Ind Co Ltd | Method for improving quality of wheat flour |
US4643876A (en) | 1985-06-21 | 1987-02-17 | Surgikos, Inc. | Hydrogen peroxide plasma sterilization system |
US5184046A (en) | 1990-09-28 | 1993-02-02 | Abtox, Inc. | Circular waveguide plasma microwave sterilizer apparatus |
RU2102084C1 (en) | 1993-04-06 | 1998-01-20 | Евгений Петрович Бельков | Method for sterilizing objects |
US5482684A (en) | 1994-05-03 | 1996-01-09 | Abtox, Inc. | Vessel useful for monitoring plasma sterilizing processes |
US5656238A (en) | 1994-10-11 | 1997-08-12 | Johnson & Johnson Medical, Inc. | Plasma-enhanced vacuum drying |
IL115130A (en) | 1995-09-01 | 1999-09-22 | Israel State | Method and device for ozone sterilization of objects |
WO1997018343A1 (en) | 1995-11-13 | 1997-05-22 | Ist Instant Surface Technology S.A. | Method and device for sterilising, deodorising and protecting the inner surfaces of containers and tubes |
RU2067003C1 (en) | 1995-12-15 | 1996-09-27 | Общество с ограниченной ответственностью Научно-производственная фирма "Плайн" | Object treating method and apparatus |
US6331514B1 (en) * | 1996-08-26 | 2001-12-18 | Stephen R. Wurzburger | Sterilizing and disinfecting compound |
US5895587A (en) | 1997-01-21 | 1999-04-20 | Cryovac, Inc. | Cook-in package and method of making same |
EP0981492A1 (en) | 1997-05-12 | 2000-03-01 | IST Instant Surface Technology S.A. | Method and device for surface treatment |
DE19719911A1 (en) | 1997-05-13 | 1998-11-19 | Max Kettner Gmbh & Co Kg I K | Device for treating beverage containers |
US6406759B1 (en) | 1998-01-08 | 2002-06-18 | The University Of Tennessee Research Corporation | Remote exposure of workpieces using a recirculated plasma |
DE19814865C2 (en) | 1998-04-02 | 2000-09-07 | Fraunhofer Ges Forschung | Process for plasma treatment in hollow bodies |
US6093432A (en) | 1998-08-13 | 2000-07-25 | University Of Guelph | Method and apparatus for electrically treating foodstuffs for preservation |
FR2790962B1 (en) | 1999-03-16 | 2003-10-10 | Absys | PLASMA STERILIZATION PROCESS AND DEVICES |
US6455014B1 (en) | 1999-05-14 | 2002-09-24 | Mesosystems Technology, Inc. | Decontamination of fluids or objects contaminated with chemical or biological agents using a distributed plasma reactor |
US20020129902A1 (en) | 1999-05-14 | 2002-09-19 | Babayan Steven E. | Low-temperature compatible wide-pressure-range plasma flow device |
US6096564A (en) | 1999-05-25 | 2000-08-01 | Wisconsin Alumni Research Foundation | Plasma-aided treatment of surfaces against bacterial attachment and biofilm deposition |
WO2000078123A1 (en) | 1999-06-24 | 2000-12-28 | Wisconsin Alumni Research Foundation | Cold-plasma treatment of seeds to remove surface materials |
US6403029B1 (en) | 2000-01-12 | 2002-06-11 | The Trustees Of Princeton University | System and method of applying energetic ions for sterilization |
KR20000053747A (en) | 2000-03-23 | 2000-09-05 | 고중석 | Vaporizer fitted Minute Quantitative Liquid Injection Device |
DE10045585A1 (en) | 2000-09-15 | 2002-03-28 | Ruediger Haaga Gmbh | Process for sterilizing and depyrogenizing washed containers |
FR2814079B1 (en) | 2000-09-15 | 2005-05-13 | Absys | PLASMA STERILIZATION SYSTEM |
US6638475B1 (en) | 2000-11-08 | 2003-10-28 | The Regents Of The University Of California | Method for inhibiting pathogenic and spoilage activity in products |
KR100434940B1 (en) | 2000-12-12 | 2004-06-10 | 한국기계연구원 | Catalyst Reactor Activated for Treating Hazardous Gas with Nonthermal Plasma and Dielectric Heating and Method Treating thereof |
US7163664B2 (en) | 2000-12-27 | 2007-01-16 | Hydro Enterprises, Inc. | Methods and devices for dispensing a potable product liquid |
US20040050682A1 (en) | 2000-12-27 | 2004-03-18 | George Paskalov | Activated water apparatus and methods and products |
DE10108717C1 (en) | 2001-02-23 | 2002-07-11 | Bosch Gmbh Robert | Apparatus for removing electric charge from a plastic sheet, paper web or polymer fibers, comprises a plasma generator producing plasma containing charged particles and rollers which feed sheet through the region containing plasma |
US20020182101A1 (en) | 2001-03-27 | 2002-12-05 | Pavel Koulik | Process and device for plasma surface treatment |
WO2002078749A2 (en) | 2001-03-28 | 2002-10-10 | The Regents Of The University Of California | Atmospheric pressure rf plasma source using ambient air and complex molecular gases |
US6811757B2 (en) | 2001-04-04 | 2004-11-02 | Ecozone Technologies Ltd. | Dielectric barrier discharge fluid purification system |
RU2199349C2 (en) | 2001-04-12 | 2003-02-27 | ГП "Красная Звезда" НПЦ "ИНТЕКО" | Method and device for carrying out dry sterilization of medical products |
US6562386B2 (en) | 2001-05-07 | 2003-05-13 | Regents Of The University Of Minnesota | Method and apparatus for non-thermal pasteurization |
US20030030374A1 (en) | 2001-08-03 | 2003-02-13 | Deepak Pai | Dielectric barrier discharge plasma reactor cell |
DE10138938A1 (en) | 2001-08-08 | 2003-02-20 | Bosch Gmbh Robert | Method for sterilizing containers in a plasma treatment chamber, involves movement of the containers and/or the plasma excitation units so that a plasma is produced in required container regions |
US20030039726A1 (en) | 2001-08-24 | 2003-02-27 | American Air Liquide Inc. | Method of treating food products using irradiation and a modified atmoshpere |
US20040208804A1 (en) | 2001-08-25 | 2004-10-21 | Hall Stephen Ivor | Non-thermal plasma reactor |
US6822250B2 (en) | 2002-03-04 | 2004-11-23 | Steris Inc. | Mobile radiant energy sterilizer |
FR2836772B1 (en) | 2002-03-04 | 2004-07-09 | Absys | GAS GENERATOR FOR A STERILIZATION SYSTEM |
US20030168009A1 (en) | 2002-03-08 | 2003-09-11 | Denes Ferencz S. | Plasma processing within low-dimension cavities |
US20040076543A1 (en) | 2002-03-18 | 2004-04-22 | Sokolowski Asaf Zeev | System and method for decontamination and sterilization of harmful chemical and biological materials |
DE10211976A1 (en) | 2002-03-19 | 2003-10-02 | Bosch Gmbh Robert | Method and device at least for the sterilization of containers and / or their closing elements |
JP2006508704A (en) | 2002-04-24 | 2006-03-16 | アピト コープ.エス.アー. | A device that uses plasma to treat the surface of a container |
AUPS220302A0 (en) | 2002-05-08 | 2002-06-06 | Chang, Chak Man Thomas | A plasma formed within bubbles in an aqueous medium and uses therefore |
JP4599023B2 (en) | 2002-06-21 | 2010-12-15 | 大日本印刷株式会社 | Method and apparatus for sterilizing packaging material using high voltage pulse power supply |
US20040216845A1 (en) | 2003-05-02 | 2004-11-04 | Czeslaw Golkowski | Non-thermal plasma generator device |
US20060027539A1 (en) | 2003-05-02 | 2006-02-09 | Czeslaw Golkowski | Non-thermal plasma generator device |
US7307243B2 (en) | 2003-05-09 | 2007-12-11 | North Carolina State University | Dynamic radiant food preparation methods and systems |
US8475723B2 (en) | 2003-07-28 | 2013-07-02 | Iono2X Engineering, L.L.C. | Dielectric barrier discharge cell with hermetically sealed electrodes and automatic washing of electrodes during operation of the cell |
US7767167B2 (en) | 2003-07-28 | 2010-08-03 | Iono2X Engineering, L.L.C. | Dielectric barrier discharge cell with hermetically sealed electrodes, apparatus and method for the treatment of odor and volatile organic compound contaminants in air emissions, and for purifying gases and sterilizing surfaces |
US6991768B2 (en) | 2003-07-28 | 2006-01-31 | Iono2X Engineering L.L.C. | Apparatus and method for the treatment of odor and volatile organic compound contaminants in air emissions |
US20050189302A1 (en) * | 2003-07-31 | 2005-09-01 | Latino Joseph S. | Viral inactivation using ozone |
RU2254143C2 (en) | 2003-09-08 | 2005-06-20 | ФГУП - Российский федеральный ядерный центр - Всероссийский научно-исследовательский институт экспериментальной физики - ФГУП-РФЯЦ-ВНИИЭФ | Method for sterilizing objects |
WO2005070018A2 (en) | 2004-01-22 | 2005-08-04 | Plasmasol Corporation | Modular sterilization system |
US7367196B2 (en) | 2004-02-23 | 2008-05-06 | Princeton Biomeditech Corporation | Spinning cold plasma apparatus and methods relating thereto |
NL1026532C2 (en) | 2004-06-30 | 2006-01-02 | Tno | Method and means for generating a plasma at atmospheric pressure. |
DE102004049783B4 (en) | 2004-10-12 | 2009-03-19 | Je Plasmaconsult Gmbh | Apparatus for processing goods with the aid of an electrical discharge |
FR2880105B1 (en) | 2004-12-23 | 2007-04-20 | Cie Financiere Alcatel Sa | DEVICE AND METHOD FOR CONTROLLING THE DEHYDRATION OPERATION DURING A LYOPHILIZATION TREATMENT |
DE102005002142A1 (en) | 2005-01-12 | 2006-07-20 | Forschungsverbund Berlin E.V. | Microplasma array |
GB0501460D0 (en) | 2005-01-25 | 2005-03-02 | Univ Edinburgh | Improved plasma cleaning method |
WO2006086271A2 (en) * | 2005-02-07 | 2006-08-17 | Jacques Elfersy | Methods and compositions for biocidal treatments |
JP2008533666A (en) | 2005-03-07 | 2008-08-21 | オールド ドミニオン ユニバーシティ リサーチ ファウンデーション | Plasma generator |
ES2430552T3 (en) | 2005-04-29 | 2013-11-21 | Vlaamse Instelling Voor Technologisch Onderzoek N.V. (Vito) | Apparatus and procedure for purification and disinfection of liquid or gaseous substances |
US8361402B2 (en) | 2005-07-20 | 2013-01-29 | Alphatech International Limited | Apparatus for air purification and disinfection |
JP5007386B2 (en) | 2005-07-28 | 2012-08-22 | 国立大学法人佐賀大学 | Radical sterilizer |
WO2007031934A2 (en) | 2005-09-15 | 2007-03-22 | Philips Intellectual Property & Standards Gmbh | Adaptive driver for dielectric barrier discharge (dbd) lamp |
US20070104610A1 (en) | 2005-11-01 | 2007-05-10 | Houston Edward J | Plasma sterilization system having improved plasma generator |
WO2007067924A2 (en) | 2005-12-07 | 2007-06-14 | Stryker Corporation | Sterilizing system with a plasma generator, the plasma generator having an electrode assembly having an array of capillaries in which the plasma is generated and into which fluid is introduced to generate sterilant |
US7967820B2 (en) | 2006-02-07 | 2011-06-28 | P Tech, Llc. | Methods and devices for trauma welding |
DE102006019664B4 (en) | 2006-04-27 | 2017-01-05 | Leibniz-Institut für Plasmaforschung und Technologie e.V. | Cold plasma hand-held device for the plasma treatment of surfaces |
DE102006020483A1 (en) | 2006-04-28 | 2007-11-08 | Fachhochschule Hildesheim/Holzminden/Göttingen | Method and device for treating seed with a physical plasma at atmospheric pressure |
US7384456B2 (en) | 2006-05-15 | 2008-06-10 | Airinspace B.V. | Modular frame for air purification devices |
US20080006536A1 (en) | 2006-05-18 | 2008-01-10 | North Carolina State University | Processing cellulosic material utilizing atmospheric-pressure plasma |
DE102006036536B3 (en) | 2006-07-31 | 2008-02-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for plasma treating a surface |
EP1884248A1 (en) | 2006-08-01 | 2008-02-06 | L'AIR LIQUIDE, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude | Continuous process for functionalisation and sterilisation of flat food packaging elements by atmospheric plasma |
CA2694244C (en) | 2006-08-02 | 2012-10-16 | Viroforce Systems Inc. | Apparatus and method for using ozone as a disinfectant |
KR100775124B1 (en) | 2006-09-07 | 2007-11-08 | 삼성전자주식회사 | System for maintaining freshness including flexible conducting polymer electrode |
US20080063559A1 (en) | 2006-09-13 | 2008-03-13 | Joseph Alexander | Fan forced electric unit that incorporates a low power cold plasma generator and method of making same |
FR2907351B1 (en) | 2006-10-18 | 2009-02-06 | Sidel Participations | PLASMA CONTAINER TREATMENT MACHINE, COMPRISING DECAL DEPRESSURIZATION AND PRESSURIZATION CIRCUITS |
US7931811B2 (en) | 2006-10-27 | 2011-04-26 | Regents Of The University Of Minnesota | Dielectric barrier reactor having concentrated electric field |
WO2008072170A2 (en) | 2006-12-15 | 2008-06-19 | Philips Intellectual Property & Standards Gmbh | Dielectric barrier discharge lamp |
WO2008096292A1 (en) | 2007-02-07 | 2008-08-14 | Philips Intellectual Property & Standards Gmbh | Dielectric barrier discharge lamp |
US20080193330A1 (en) | 2007-02-09 | 2008-08-14 | Tokyo Institute Of Technology | surface treatment apparatus |
CN101678135A (en) | 2007-04-11 | 2010-03-24 | 欧雷克斯安卓·柏里苏维奇·扎吉卡 | Carry out the method and the device for carrying out said thereof of water and aqueous solution processing with the plasma of gas discharge |
WO2008126068A1 (en) | 2007-04-11 | 2008-10-23 | University Of Limerick | A plasma system |
DK1982734T3 (en) | 2007-04-19 | 2011-10-17 | Akos Advanced Technology Ltd | Liquid purification method and apparatus |
CN101743785B (en) | 2007-05-11 | 2012-11-14 | 力技术公司 | Enhancing plasma surface modification using high intensity and high power ultrasonic acoustic waves |
WO2008144499A1 (en) | 2007-05-16 | 2008-11-27 | Old Dominion Univesity Research Foundation | System and methods for pasteurizing food using ultrashort electrical pulses |
US8097217B2 (en) | 2007-07-06 | 2012-01-17 | Uion Co., Ltd | Atmospheric pressure plasma generating apparatus by induction electrode |
DE102007037406A1 (en) | 2007-08-08 | 2009-06-04 | Neoplas Gmbh | Method and device for plasma assisted surface treatment |
WO2009041861A1 (en) | 2007-09-25 | 2009-04-02 | Sik Institutet För Livsmedel Och Bioteknik Ab | Device and method for lifting and handling of objects |
EP2206521B1 (en) | 2007-09-27 | 2019-07-17 | Satoshi Ikawa | Apparatus for sterilization |
WO2009040130A1 (en) | 2007-09-28 | 2009-04-02 | Danmarks Tekniske Universitet | Method for sterilization of objects |
US9757487B2 (en) | 2007-11-21 | 2017-09-12 | University Of Florida Research Foundation, Inc. | Self-sterilizing device using plasma fields |
US8268136B2 (en) | 2007-12-20 | 2012-09-18 | McCutchen, Co. | Electrohydraulic and shear cavitation radial counterflow liquid processor |
WO2009098662A1 (en) | 2008-02-08 | 2009-08-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Long lifetime system for the generation of surface plasmas |
US8115135B2 (en) | 2008-02-14 | 2012-02-14 | Adventix Technologies Inc. | Plasma assisted oxygen decontaminant generator and sprayer |
SE531797C2 (en) | 2008-04-07 | 2009-08-04 | Paer H Henriksson | Arrangement and method for damaging microorganisms with an electric field and uses of the arrangement |
US20090274592A1 (en) | 2008-05-01 | 2009-11-05 | Airlnspace B.V. | Plasma-based air purification device including carbon pre-filter and/or self-cleaning electrodes |
US7621985B1 (en) | 2008-05-24 | 2009-11-24 | Adventix Technologies Inc. | Plasma torch implemented air purifier |
US20090297409A1 (en) | 2008-05-30 | 2009-12-03 | Buchanan Walter R | Discharge plasma reactor |
CA2733163C (en) | 2008-08-08 | 2013-11-19 | Chokichi Sato | Water vapor plasma generating apparatus, sterilization and disinfection method, and method for antioxidative treatment using water vapor plasma |
WO2010022160A2 (en) | 2008-08-19 | 2010-02-25 | Drexel University | Nano discharges in liquids |
ITMI20081993A1 (en) | 2008-11-11 | 2010-05-12 | Francesco Mazzariello | METHOD AND PLANT FOR SANITIZING FOOD PRODUCTS CONTAMINATED BY MYCOTOSSINS |
US9363880B2 (en) | 2009-03-24 | 2016-06-07 | Purdue Research Foundation | Method and system for treating packaged products |
GB0906091D0 (en) | 2009-04-07 | 2009-05-20 | Snowball Malcolm R | None invasive disinfector |
US8372460B2 (en) | 2009-07-10 | 2013-02-12 | L'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | System and method for non-thermal plasma treatment of foodstuffs |
CN102625730B (en) | 2009-09-03 | 2014-03-12 | 国立大学法人大阪大学 | Method and device for supplying ions to liquid, and method and device for sterilizing |
US8128869B2 (en) * | 2009-10-05 | 2012-03-06 | Hussmann Corporation | Air sanitization system with variable speed fan |
GB0919274D0 (en) | 2009-11-03 | 2009-12-16 | Univ The Glasgow | Plasma generation apparatus and use of plasma generation apparatus |
US20110115415A1 (en) | 2009-11-16 | 2011-05-19 | Kun-Liang Hong | Low ozone ratio, high-performance dielectric barrier discharge reactor |
WO2011110191A1 (en) | 2010-03-10 | 2011-09-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Method and arrangement for treating an object with a low- temperature plasma |
DE102010003284A1 (en) | 2010-03-25 | 2011-09-29 | Dot Gmbh | Process for the chemical activation of working gases in closed volumes |
US20130330229A1 (en) | 2010-03-31 | 2013-12-12 | Drexel University | Plasma system for air sterilization |
FR2958187B1 (en) | 2010-04-01 | 2012-06-15 | Centre Nat Rech Scient | DEVICE FOR PRODUCING A CHEMICAL SPECIES FROM A FLUID BY USING A MICROWAVE RESONANT STRUCTURE |
US20110268850A1 (en) | 2010-04-30 | 2011-11-03 | Vashui Rasanayagam | Modified atmosphere packaging gas, method for non-thermal plasma treatment of article, and article of manufacture for use therein |
DE102010026104B3 (en) | 2010-07-05 | 2011-12-01 | Fresenius Medical Care Deutschland Gmbh | Method for sterilizing at least one article, sterilization device and use thereof |
CN101912761B (en) | 2010-07-05 | 2014-02-19 | 洪昆喨 | Dielectric discharge reactor of uniform electric field |
FR2965179B1 (en) | 2010-09-24 | 2013-04-26 | C R I T T Materiaux Depots Et Traitement De Surface | DEVICE FOR COLD PLASMA STERILIZATION OF AN OBJECT, SUCH AS A MEDICAL DEVICE, AN IMPLANT OR OTHER AND METHOD USING THE SAME |
DE102010062874A1 (en) | 2010-12-13 | 2012-06-14 | Hilti Aktiengesellschaft | Hand tool |
US20120156340A1 (en) | 2010-12-20 | 2012-06-21 | Vasuhi Rasanayagam | Plasma Generation of CO for Modified Atmosphere Packaging |
US8551546B2 (en) | 2010-12-20 | 2013-10-08 | American Air Liquide, Inc. | Plasma generation of CO for modified atmosphere packaging |
DE102011009056B4 (en) | 2011-01-20 | 2016-04-07 | Schott Ag | Apparatus for the plasma treatment of hollow bodies |
DE102011003782A1 (en) | 2011-02-08 | 2012-08-09 | Meiko Maschinenbau Gmbh & Co. Kg | Cleaning device for cleaning items to be cleaned |
NL2006212C2 (en) | 2011-02-16 | 2012-08-20 | Synthesis B V | Device and method for disinfecting plant seeds. |
WO2012113568A1 (en) | 2011-02-25 | 2012-08-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Disinfection appliance, container, use of a container and disinfection method for disinfecting a container, in particular for a food container |
US9220162B2 (en) | 2011-03-09 | 2015-12-22 | Samsung Electronics Co., Ltd. | Plasma generating apparatus and plasma generating method |
DE102011016448A1 (en) | 2011-03-29 | 2012-10-04 | Khs Corpoplast Gmbh | Method for sterilizing and device for blow molding of containers |
GB201107692D0 (en) | 2011-05-09 | 2011-06-22 | Snowball Malcolm R | Sterilisation of packed articles |
US20130164173A1 (en) | 2011-06-24 | 2013-06-27 | Elwood G. Norris | Plasma emitter |
TWI461113B (en) | 2011-08-24 | 2014-11-11 | Nat Univ Tsing Hua | Atmospheric pressure plasma jet device |
US9107538B2 (en) | 2011-11-01 | 2015-08-18 | Pepsico, Inc. | Cold plasma sanitation for a dispensing machine |
JP6083093B2 (en) | 2011-11-11 | 2017-02-22 | 国立大学法人佐賀大学 | Plasma generator |
WO2013076102A1 (en) | 2011-11-22 | 2013-05-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method and device for generating a non-thermal plasma having a predetermined ozone concentration |
GB2496879A (en) | 2011-11-24 | 2013-05-29 | Creo Medical Ltd | Gas plasma disinfection and sterilisation |
US20130156641A1 (en) | 2011-12-12 | 2013-06-20 | Applied Quantum Energy Llc | Sterilization Using Plasma Generated NOx |
JP6317927B2 (en) | 2012-01-09 | 2018-04-25 | ムー・メディカル・デバイスズ・エルエルシーMoe Medical Devices Llc | Plasma assisted skin treatment |
US8747972B2 (en) | 2012-01-31 | 2014-06-10 | Dai Nippon Printing Co., Ltd. | Packaging material for boil/retort treatment and pouch |
KR101391708B1 (en) | 2012-06-07 | 2014-05-07 | 한국식품연구원 | Method for sterilizing of packaged food using atmospheric plasma and packaged food made by the same |
US8834803B2 (en) | 2012-10-19 | 2014-09-16 | Hussmann Corporation | Electro hydrodynamic thruster for decontaminating a display case |
US9067788B1 (en) | 2012-11-01 | 2015-06-30 | Rick B. Spielman | Apparatus for highly efficient cold-plasma ozone production |
CN103039151B (en) | 2012-12-07 | 2015-09-02 | 常州中科常泰等离子体科技有限公司 | Cold plasma seed-treating apparatus |
US9295280B2 (en) | 2012-12-11 | 2016-03-29 | Plasmology4, Inc. | Method and apparatus for cold plasma food contact surface sanitation |
DE102013003865B4 (en) | 2013-03-06 | 2018-09-13 | Al-Ko Therm Gmbh | Method and device for cleaning an article |
MX369455B (en) | 2013-03-15 | 2019-11-08 | Archer Daniels Midland Co | Improved methods for treating grain with ozone. |
DK3016493T3 (en) | 2013-07-04 | 2023-01-23 | Vilmorin & Cie | Treatment for disinfecting seeds |
DE102014107805A1 (en) | 2013-07-17 | 2015-01-22 | Vorwerk & Co. Interholding Gmbh | Arrangement for filtering air and method for air purification |
AU2014318369B2 (en) | 2013-09-16 | 2018-10-18 | Mars, Incorporated | Food sanitization |
NL2013151C2 (en) | 2013-10-30 | 2015-05-04 | Johannes Adrianus Maria Hoefnagels | Process for the treatment of fruits and vegetables. |
GB201322387D0 (en) | 2013-12-18 | 2014-02-05 | Dublin Inst Of Technology | A method for reducing the oil content of snacks by increasing spreadsheet |
US9560860B2 (en) | 2014-05-15 | 2017-02-07 | Tim Zwijack | Apparatus and method for decontaminating grain |
WO2015200907A1 (en) | 2014-06-27 | 2015-12-30 | EP Technologies LLC | Treated sprout plants with decreased bacterial viability and methods and apparatuses for making the same |
EP3166413B1 (en) | 2014-07-08 | 2020-05-13 | Johannes Adrianus Maria Hoefnagels | Process for the treatment of biological material |
WO2016140447A1 (en) | 2015-03-03 | 2016-09-09 | Plasmapp Co., Ltd. | Plasma treatment method for processed meat product and plasma treatment apparatus for processed meat product |
US20190224354A1 (en) | 2015-07-24 | 2019-07-25 | The Board Of Regents For Oklahoma State University | Cold plasma devices for decontamination of foodborne human pathogens |
US10194672B2 (en) | 2015-10-23 | 2019-02-05 | NanoGuard Technologies, LLC | Reactive gas, reactive gas generation system and product treatment using reactive gas |
DE102015119369A1 (en) | 2015-11-10 | 2017-05-11 | INP Leipniz-Institut für Plalsmaforschung und Technologie e.V. | Apparatus, system and method for treating an object with plasma |
JP6649754B2 (en) | 2015-11-24 | 2020-02-19 | 日本特殊陶業株式会社 | Plasma reactor |
US10668180B2 (en) | 2016-03-02 | 2020-06-02 | Asp Global Manufacturing Gmbh | Apparatus and method for sterilizing medical devices |
JP2019534531A (en) | 2016-09-02 | 2019-11-28 | ソムニオ グローバル ホールディングス,エルエルシー | Apparatus and method for free radical generation |
CA3084252A1 (en) | 2017-03-28 | 2018-10-04 | Caribou Biosciences, Inc. | Crispr-associated (cas) protein |
CN108310425B (en) | 2018-02-02 | 2021-02-12 | 毕玉亮 | Automatic sterilizer for greenhouse |
US10925144B2 (en) | 2019-06-14 | 2021-02-16 | NanoGuard Technologies, LLC | Electrode assembly, dielectric barrier discharge system and use thereof |
US11896731B2 (en) | 2020-04-03 | 2024-02-13 | NanoGuard Technologies, LLC | Methods of disarming viruses using reactive gas |
-
2020
- 2020-09-10 US US17/017,517 patent/US11896731B2/en active Active
-
2021
- 2021-03-24 CA CA3171198A patent/CA3171198A1/en active Pending
- 2021-03-24 MX MX2022012346A patent/MX2022012346A/en unknown
- 2021-03-24 EP EP21721663.9A patent/EP4126081A2/en active Pending
- 2021-03-24 BR BR112022019825A patent/BR112022019825A2/en unknown
- 2021-03-24 KR KR1020227038433A patent/KR20220164023A/en active Search and Examination
- 2021-03-24 AU AU2021247032A patent/AU2021247032A1/en active Pending
- 2021-03-24 WO PCT/US2021/023941 patent/WO2021202201A2/en unknown
- 2021-03-24 CN CN202180039377.6A patent/CN116033928A/en active Pending
- 2021-03-24 JP JP2022559960A patent/JP2023520787A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130189156A1 (en) | 2009-03-24 | 2013-07-25 | Purdue Research Foundation | Method and system for treating packaged products |
US20140044595A1 (en) | 2009-03-24 | 2014-02-13 | Purdue Research Foundation | Generation of microbiocide inside a package utilizing a controlled gas composition |
Non-Patent Citations (26)
Title |
---|
"Influenza Type A Viruses", CENTERS FOR DISEASE CONTROL AND PREVENTION, 19 April 2017 (2017-04-19), Retrieved from the Internet <URL:https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm> |
ALSHRAIEDEH N. H.ALKAWAREEK M. Y.GORMAN S. P.GRAHAM W. G.GILMORE B. F.: "Atmospheric pressure, nonthermal plasma inactivation of MS2 bacteriophage: effect of oxygen concentration on virucidal activity", J. APPL. MICROBIOL., vol. 115, 2013, pages 1420 - 1426 |
AUBRY MRICHARD VGREEN JBROULT JMUSSO D: "Inactivation of Zika virus in Plasma with Amotosalen and Ultraviolet A Illumination", TRANSFUSION, vol. 56, 2016, pages 33 - 40, XP055716960, DOI: 10.1111/trf.13271 |
BAE S.C.PARK S.Y.CHOE W.HA S. D.: "Inactivation of murine norovirus-1 and hepatitis A virus on fresh meats by atmospheric pressure jets", FOOD RES. INT., vol. 76, 2015, pages 342 - 347, XP029262395, DOI: 10.1016/j.foodres.2015.06.039 |
BRIE, A. ET AL.: "Inactivation of murine norovirus and hepatitis A virus on fresh raspberries by gaseous ozone treatment", FOOD MICROBIOL., vol. 70, 2018, pages 1 - 6, XP085253854, DOI: 10.1016/j.fm.2017.08.010 |
BUTOT SPUTALLAZ TSANCHEZ, G: "Procedure for Rapid Concentration and Detection of Entric Viruses from Berries and Vegetables", APPL ENVIRON MICROBIOL, vol. 73, no. 1, 2007, pages 186 - 192 |
COWLING BJ ET AL.: "Aerosol transmission is an important mode of influenza A virus spread.", NAT COMMUN., vol. 4, 2013, pages 1935 |
EPA, GUIDANCE TO REGISTRANTS: PROCESS FOR MAKING CLAIMS AGAINST EMERGING VIRAL PATHOGENS NOT ON EPA-REGISTERED DISINFECTANT LABELS, 19 August 2016 (2016-08-19) |
GUIDANCE TO REGISTRANTS: PROCESS FOR MAKING CLAIMS AGAINST EMERGING VIRAL PATHOGENS NOT ON EPA-REGISTERED DISINFECTANT LABELS, 19 August 2016 (2016-08-19) |
GWYNETH V. CAREY-SMITHCRAIG BILLINGTONANGELA J. CORNELISJ. ANDREW HUDSONJACK A. HEINEMANN: "Isolation and Characterization of Bacteriophage Infecting Salmonella spp", FEMS MICROBIOL LETT, vol. 258, 2006, pages 182 - 186 |
HAKDONG SHINJU-HOON LEEHYERYEN KIMYOUNHO CHOISUNGGI HEUSANGRYEOL RYU: "Receptor Diversity and Host Interaction of Bacteriophage Infecting Salmonella enterica Serovar Typhimurium", PLOS ONE, vol. 7, no. 8, 2012, pages e43392 |
HUDSON JB ET AL.: "Development of a Practical Method for Using Ozone Gas as a Virus Decontaminating Agent", OZONE: SCIENCE & ENGINEERING, vol. 31, 2009, pages 216 |
IAN COCKKALT F. R.: "A modified MS2 bacteriophage plaque reduction assay for rapid screening of antiviral plant extracts", PHARMACOGNOSY RES, vol. 2, no. 4, 2010, pages 221 - 228 |
JANIS A. MULLERMIRJA HARMSAXEL SCHUBERTBENJAMIN MAYERSTEPHANIE JANSENJEAN-PHILIPPEDETLEF MICHAELTHOMAS MERTENSOLLI VAPALAHTIJONAS : "Development of a high-throughput colorimetric Zika virus Infection Assay", MED. MICROBIOL IMMUNOL, vol. 206, 2017, pages 175 - 185, XP036193834, DOI: 10.1007/s00430-017-0493-2 |
JOELLE WOOLSTONADAM R. PARKSTAMAR ABULADZEBRADLEY ANDERSONMANRONG LICHANDI CARTELEIGH FARRIS HANNASERENA HEYSEDUANE CHARBONNEAUALE: "Bacteriophage lytic for Salmonella Rapidly Reduce Salmonella Contamination on glass and Stainless-steel Surfaces", LANDES BIOSCIENCE; BACTERIOPHAGE, vol. 3, no. 3, 2013, pages e25697 - 1 |
KUZMANOVIC, D.A. ET AL.: "Bacteriophage MS2: Molecular Weight and Spatial Distribution of the Protein and RNA Components by Small-Angle Neutron Scattering and Virus Counting", STRUCTURE, vol. 11, 2003, pages 1339 - 1348 |
MULLER JAHARMS MSCHUBERT AJANSEN SMICHAEL DMERTENS TSCHMIDT-CHANASIT JMUNCH J: "Inactivation and Environmental Stability of Zika virus", EMERG INFECT DIS, vol. 22, 2016, pages 1685 - 1687 |
NITZAN SOFFERTAMAR ABULADZEJOELLE WOOLSTONMANRONG LILEIGH FARRIS HANNASERENA HEYSEDUANE CHARBONNEAUALEXANDER SULAKVELIDZE: "Bacteriophage Safety Reduce Salmonell Contamination in Pet Food and Raw Pet Food Ingredients", TAYLOR& FRANCIS GROUP, BACTERIOPHAGE, vol. 6, no. 3, 2016, pages e1220347 |
OZONE AS A DISINFECTANT TO DESTROY PATHOGENS, LIKE THE CORONAVIRUS, 13 March 2020 (2020-03-13), Retrieved from the Internet <URL:www.ozonesolutions.com/knowledge-center/use-ozone-as-a-disinfectant-to-destroy-pathogens-like-thecoronavirus.html> |
OZONE EFFECTS ON PATHOGENS, 13 March 2020 (2020-03-13), Retrieved from the Internet <URL:www.ozonesolutions.com/knowledge-center/ozone-effects-on-pathogens.html> |
PULIGUNDIA PRADEEPMOK CHULKYOON: "Non-thermal plasmas (NTPs) for inactivation of viruses in abiotic environment", RES. J. BIOTECH., vol. 11, no. 6, 2016, pages 91 - 96 |
RASMUSSEN SAJAMIESON DJHONEIN MAPETERSEN LR: "Zika virus and Birth Defects-Reviewing the evidence for Causality", N. ENGL J. MED, 2016, pages 3741981 - 1987 |
WHO, ZIKA VIRUS SITUATION REPORT, 5 February 2016 (2016-02-05) |
WOLF, C. ET AL.: "Proxies to monitor the inactivation of viruses by ozone in surface water and wastewater effluent", WATER RESEARCH, vol. 166, 2019, XP085862766, DOI: 10.1016/j.watres.2019.115088 |
WU Y.LIANG Y.WEI K.LI W.YAO M.ZHANG, J.GRINSHPUN S.A.: "MS2 virus inactivation by atmospheric-pressure cold plasma using different gas carriers and power levels", APPL. ENVIRON. MICROBIOL., vol. 81, 2015, pages 996 - 1002 |
YASUDA H.MIURA T.KURITA H.TAKASHIMA K.MIZUNO A.: "Biological evaluation of DNA damage in bacteriophage inactivated by atmospheric pressure cold plasma", PLASMA PROCESS POLYM., vol. 7, 2010, pages 301 - 308, XP055673235, DOI: 10.1002/ppap.200900088 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11882844B2 (en) | 2015-10-23 | 2024-01-30 | NanoGuard Technologies, LLC | Reactive gas, reactive gas generation system and product treatment using reactive gas |
US11896731B2 (en) | 2020-04-03 | 2024-02-13 | NanoGuard Technologies, LLC | Methods of disarming viruses using reactive gas |
Also Published As
Publication number | Publication date |
---|---|
EP4126081A2 (en) | 2023-02-08 |
MX2022012346A (en) | 2022-10-27 |
AU2021247032A1 (en) | 2022-10-06 |
US11896731B2 (en) | 2024-02-13 |
US20210308309A1 (en) | 2021-10-07 |
WO2021202201A3 (en) | 2021-12-02 |
KR20220164023A (en) | 2022-12-12 |
CN116033928A (en) | 2023-04-28 |
BR112022019825A2 (en) | 2022-11-16 |
CA3171198A1 (en) | 2021-10-07 |
JP2023520787A (en) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aboubakr et al. | Virucidal effect of cold atmospheric gaseous plasma on feline calicivirus, a surrogate for human norovirus | |
Su et al. | Inactivation efficacy of nonthermal plasma-activated solutions against Newcastle disease virus | |
Pradeep et al. | Non-thermal plasmas (NTPs) for inactivation of viruses in abiotic environment | |
Scholtz et al. | Nonthermal plasma—A tool for decontamination and disinfection | |
Guo et al. | Bactericidal effect of various non-thermal plasma agents and the influence of experimental conditions in microbial inactivation: A review | |
US11896731B2 (en) | Methods of disarming viruses using reactive gas | |
Alimohammadi et al. | Effectiveness of ozone gas on airborne virus inactivation in enclosed spaces: a review study | |
Xia et al. | Inactivation of airborne porcine reproductive and respiratory syndrome virus (PRRSv) by a packed bed dielectric barrier discharge non-thermal plasma | |
Nayak et al. | Rapid inactivation of airborne porcine reproductive and respiratory syndrome virus using an atmospheric pressure air plasma | |
Rothrock et al. | In-package inactivation of pathogenic and spoilage bacteria associated with poultry using dielectric barrier discharge-cold plasma treatments | |
Schnabel et al. | Inactivation of vegetative microorganisms and Bacillus atrophaeus endospores by reactive nitrogen species (RNS) | |
JP2013537433A (en) | Plasma generated gas sterilization method | |
Assadi et al. | Review on inactivation of airborne viruses using non-thermal plasma technologies: From MS2 to coronavirus | |
WO2022166417A1 (en) | Cold-chain food product outer package disinfecting and sterilizing system for novel coronavirus | |
US11633511B2 (en) | Production of immune-response-stimulating aerosols by non-thermal plasma treatment of airborne pathogens | |
Park et al. | Assessment of cold oxygen plasma technology for the inactivation of major foodborne viruses on stainless steel | |
Hati et al. | Nonthermal plasma technology and its potential applications against foodborne microorganisms | |
Lee et al. | Inactivation of Salmonella Typhimurium on red chili peppers by treatment with gaseous chlorine dioxide followed by drying | |
Jenns et al. | Inactivation of foodborne viruses: Opportunities for cold atmospheric plasma | |
FI119679B (en) | Method and apparatus for gas sterilization | |
Sahun et al. | Inactivation of SARS-CoV-2 and other enveloped and non-enveloped viruses with non-thermal plasma for hospital disinfection | |
Zver et al. | Non-thermal plasma inactivation of viruses in water solutions | |
Salarieh et al. | Sterilization of turmeric by atmospheric pressure dielectric barrier discharge plasma | |
JP2010166855A (en) | Processing method for long storage of cereal, cereals processed to be storable for long, and processing apparatus for long storage of cereal | |
Obrová et al. | Decontamination of high-efficiency mask filters from respiratory pathogens including SARS-CoV-2 by non-thermal plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21721663 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3171198 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022559960 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021247032 Country of ref document: AU Date of ref document: 20210324 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019825 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227038433 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021721663 Country of ref document: EP Effective date: 20221103 |
|
ENP | Entry into the national phase |
Ref document number: 112022019825 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220930 |